Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

[1]  C. B. Smith,et al.  Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome , 2009, Neuroscience Letters.

[2]  J. Woodgett,et al.  Unique and Overlapping Functions of GSK-3 Isoforms in Cell Differentiation and Proliferation and Cardiovascular Development* , 2009, Journal of Biological Chemistry.

[3]  R. Jope,et al.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential , 2009, Neuropharmacology.

[4]  D. Nguyen,et al.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.

[5]  Z. Marinova,et al.  The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons , 2009, Molecular Psychiatry.

[6]  C. Belzung,et al.  Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal , 2008, Psychoneuroendocrinology.

[7]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[8]  I. Weiler,et al.  Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome , 2008, Journal of developmental and behavioral pediatrics : JDBP.

[9]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[10]  C. B. Smith,et al.  Unaltered hormonal response to stress in a mouse model of fragile X syndrome , 2008, Psychoneuroendocrinology.

[11]  D. Nelson,et al.  Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. , 2008, Behavioral neuroscience.

[12]  M. Bear,et al.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome , 2008, The Journal of physiology.

[13]  K. M. Huber,et al.  Homer Interactions Are Necessary for Metabotropic Glutamate Receptor-Induced Long-Term Depression and Translational Activation , 2008, The Journal of Neuroscience.

[14]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[15]  G. Lynch,et al.  Brain-Derived Neurotrophic Factor Rescues Synaptic Plasticity in a Mouse Model of Fragile X Syndrome , 2007, The Journal of Neuroscience.

[16]  Stephen T Warren,et al.  Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors , 2007, Proceedings of the National Academy of Sciences.

[17]  H. Manji,et al.  Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium , 2007, Neuropsychopharmacology.

[18]  C. Soldatos,et al.  Enhancing effects of chronic lithium on memory in the rat , 2007, Behavioural Brain Research.

[19]  S. Leurgans,et al.  Treatment trial of lithium to target the underlying defect in fragile X syndrome , 2006 .

[20]  M. Roh,et al.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.

[21]  M. Medina,et al.  Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors , 2006 .

[22]  F. Nicoletti,et al.  Endogenously activated mGlu5 metabotropic glutamate receptors sustain the increase in c‐Myc expression induced by leukaemia inhibitory factor in cultured mouse embryonic stem cells , 2006, Journal of neurochemistry.

[23]  Wim E Crusio,et al.  Fmr1 KO Mice as a Possible Model of Autistic Features , 2006, TheScientificWorldJournal.

[24]  T. Steckler,et al.  Transgenic Mice Overexpressing Glycogen Synthase Kinase 3β: A Putative Model of Hyperactivity and Mania , 2006, The Journal of Neuroscience.

[25]  S. Warren,et al.  Transcription, translation and fragile X syndrome. , 2006, Current opinion in genetics & development.

[26]  D. Zheleva,et al.  Targeting glycogen synthase kinase-3 in insulin signalling , 2006, Expert opinion on therapeutic targets.

[27]  K. Maiese,et al.  Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. , 2006, Current neurovascular research.

[28]  Wim E. Crusio,et al.  Social behavior deficits in the Fmr1 mutant mouse , 2006, Behavioural Brain Research.

[29]  R. Jope.  Lithium, the Seminal GSK‐3 Inhibitor , 2006 .

[30]  C. Smith,et al.  A null mutation for Fmr1 in female mice: Effects on regional cerebral metabolic rate for glucose and relationship to behavior , 2005, Neuroscience.

[31]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[32]  K. Marquis,et al.  The inhibition of glycogen synthase kinase 3β by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Aβ peptides , 2005 .

[33]  R. Paylor,et al.  Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome , 2005, Genes, brain, and behavior.

[34]  B. Oostra,et al.  A Reduced Number of Metabotropic Glutamate Subtype 5 Receptors Are Associated with Constitutive Homer Proteins in a Mouse Model of Fragile X Syndrome , 2005, The Journal of Neuroscience.

[35]  P. Hagerman,et al.  Recent advances in fragile X: a model for autism and neurodegeneration , 2005, Current opinion in psychiatry.

[36]  H. Manji,et al.  The Anti-Apoptotic, Glucocorticoid Receptor Cochaperone Protein BAG-1 Is a Long-Term Target for the Actions of Mood Stabilizers , 2005, The Journal of Neuroscience.

[37]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[38]  F. Liu,et al.  The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. , 2005, Journal of neurochemistry.

[39]  R. E. Brown,et al.  A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse , 2004, Genes, brain, and behavior.

[40]  A. Mørk,et al.  The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels , 2004, Brain Research.

[41]  R. Nitsch,et al.  The impact of genetic background on neurodegeneration and behavior in seizured mice , 2004, Genes, brain, and behavior.

[42]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Haploinsufficiency Mimics the Behavioral and Molecular Effects of Lithium , 2004, The Journal of Neuroscience.

[43]  M. Barrot,et al.  Essential role of brain-derived neurotrophic factor in adult hippocampal function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[45]  F. Liu,et al.  Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. , 2004, Biochemistry.

[46]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[47]  R. Jope.  Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. , 2003, Trends in pharmacological sciences.

[48]  F. Angelucci,et al.  Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. , 2003, The international journal of neuropsychopharmacology.

[49]  N. Cosford,et al.  In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). , 2003, European journal of pharmacology.

[50]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[51]  Xiaohua Li,et al.  Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium , 2002, Neuropharmacology.

[52]  C. B. Smith,et al.  Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Darci M. Nielsen,et al.  Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome , 2002, Brain Research.

[55]  Sanne de Wit,et al.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse , 2002, Hippocampus.

[56]  C. Phiel,et al.  Molecular targets of lithium action. , 2003, Annual review of pharmacology and toxicology.

[57]  Y. Okamoto,et al.  Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain , 2001, Psychopharmacology.

[58]  R. Porsolt,et al.  Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice , 2007, Current protocols in pharmacology.

[59]  Takaaki AbeS,et al.  Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR 5 Coupled to Inositol Phosphate / Ca 2 + Signal Transduction , 2001 .

[60]  D. Nelson,et al.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. , 2000, Human molecular genetics.

[61]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[62]  R. Jope.  Anti-bipolar therapy: mechanism of action of lithium , 1999, Molecular Psychiatry.

[63]  James R. Woodgett,et al.  Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells , 1996, Current Biology.

[64]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Hogg.  A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety , 1996, Pharmacology Biochemistry and Behavior.

[66]  R. D'Hooge,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[67]  S. Nakanishi,et al.  Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. , 1992, The Journal of biological chemistry.

[68]  Ben A. Oostra,et al.  Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.